NRF1 and hematologic disorder: These findings suggest that blocking the TCF11/Nrf1-mediated proteasome re-synthesis (or bounce-back response) can be advantageous in combination with proteasome inhibitors for treatment of hematological malignancies, and could also expand the use of proteasome inhibitors to solid tumors.